Jonathan Rubin - 18 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Chief Medical Officer
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
18 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 16:47:37 UTC
Previous filing
26 Sep 2025
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rubin Jonathan SVP, Chief Medical Officer C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 20 Feb 2026 0001836067

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SUPN Common Stock 11,284 18 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Award $0 +13,500 $0.000000 13,500 18 Feb 2026 Common Stock 13,500 $50.20 Direct F2
transaction SUPN Restricted Stock Unit Award $0 +3,000 $0.000000 3,000 18 Feb 2026 Common Stock 3,000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 269 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2 The option vests in four equal annual installments beginning on February 18, 2027.
F3 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F4 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.